A new national clinical guideline designed to prevent, diagnose and treat potentially fatal blood clots has been launched by the HSE. “Eve’s Protocol” is named in memory of Eve Cleary, who tragically died from venous thromboembolism, and aims to save lives across Irish hospitals including those serving Cork and Munster.
The HSE’s new National Clinical Guideline for Venous Thromboembolism (VTE) addresses a condition that affects approximately 5,000 people annually in Ireland. VTE, which includes deep vein thrombosis and pulmonary embolism, will affect more than one in 12 people during their lifetime, with risk increasing dramatically with age.
The guideline, developed by a 75-member multidisciplinary team established in June 2024, reflects international best practice and aims to standardise VTE care across all Irish hospitals. This means patients in Cork University Hospital, Mercy University Hospital and other local facilities will receive consistent, high-quality treatment.
Most concerning is the lack of public awareness: in one survey, 75% of adults had never heard of deep vein thrombosis, and fewer than one in 10 could name a symptom. The majority of VTE events occur during or within 90 days of a hospital stay, making early recognition crucial.
Melanie Cleary, Eve’s mother, said:
“We are so proud to see the implementation of Eve’s guidelines and all that’s been achieved in Eve’s name. These national clinical guidelines will save lives. While you can never stop blood clots, these guidelines will stop the complications attached to VTE. Eve’s legacy will live on.”
Dr Colm Henry, Chief Clinical Officer at the HSE, added:
“Enhanced awareness of VTE is critical to reducing the harm associated with this condition which can occur in all settings. Eve’s Protocol addresses this need, raising awareness of its signs and symptoms among both patients and healthcare practitioners.”
The protocol focuses on four key areas: improving patient safety through clear prevention guidance, promoting evidence-based best practices, standardising hospital care nationwide, and supporting both clinicians and patients with user-friendly diagnostic tools.
Professor Fionnuala Ní Áinle, Consultant Haematologist and Clinical Lead for the National Clinical Programme in VTE, explained:
“Many cases of VTE go undiagnosed until serious complications develop. This guideline is designed to change that, ensuring we identify those at risk, raise awareness among patients and staff, and provide a structured approach to care.”
Key warning signs include swelling or pain in one leg or arm, warmth or redness, shortness of breath, chest pain when breathing deeply, and coughing up blood. Anyone experiencing these symptoms requires urgent medical attention.
The guideline emphasises prevention through appropriate risk assessment, particularly for high-risk groups including hospitalised patients, cancer patients, pregnant women, and those with immobilised limbs. Patient education materials have been developed alongside the clinical guidance and are available on the HSE website.
Ann Marie O’Neill, CEO of Thrombosis Ireland, welcomed the launch:
“Implementation of this VTE National Guideline will be crucial for clinicians and patients alike to ensure the same high-quality prevention, diagnosis, treatment and recovery supports in every hospital nationwide.”
The comprehensive patient resources provide clear information about diagnosis, treatment options and recovery support, empowering patients and their families with essential knowledge about this potentially life-threatening condition.